Institute for Applied Clinical Sciences, Keele University, Keele, UK.
Keele University, Keele, UK.
Health Technol Assess. 2018 Mar;22(14):1-88. doi: 10.3310/hta22140.
Stroke is a major cause of death and disability worldwide. Hypoxia is common after stroke and is associated with worse outcomes. Oxygen supplementation could prevent hypoxia and secondary brain damage.
(1) To assess whether or not routine low-dose oxygen supplementation in patients with acute stroke improves outcome compared with no oxygen; and (2) to assess whether or not oxygen given at night only, when oxygen saturation is most likely to be low, is more effective than continuous supplementation.
Multicentre, prospective, randomised, open, blinded-end point trial.
Secondary care hospitals with acute stroke wards.
Adult stroke patients within 24 hours of hospital admission and 48 hours of stroke onset, without definite indications for or contraindications to oxygen or a life-threatening condition other than stroke.
Allocated by web-based minimised randomisation to: (1) continuous oxygen: oxygen via nasal cannula continuously (day and night) for 72 hours after randomisation at a flow rate of 3 l/minute if baseline oxygen saturation was ≤ 93% or 2 l/minute if > 93%; (2) nocturnal oxygen: oxygen via nasal cannula overnight (21:00-07:00) for three consecutive nights. The flow rate was the same as the continuous oxygen group; and (3) control: no routine oxygen supplementation unless required for reasons other than stroke.
Primary outcome: disability assessed by the modified Rankin Scale (mRS) at 3 months by postal questionnaire (participant aware, assessor blinded). Secondary outcomes at 7 days: neurological improvement, National Institutes of Health Stroke Scale (NIHSS), mortality, and the highest and lowest oxygen saturations within the first 72 hours. Secondary outcomes at 3, 6, and 12 months: mortality, independence, current living arrangements, Barthel Index, quality of life (European Quality of Life-5 Dimensions, three levels) and Nottingham Extended Activities of Daily Living scale by postal questionnaire.
In total, 8003 patients were recruited between 24 April 2008 and 17 June 2013 from 136 hospitals in the UK [continuous, = 2668; nocturnal, = 2667; control, = 2668; mean age 72 years (standard deviation 13 years); 4398 (55%) males]. All prognostic factors and baseline characteristics were well matched across the groups. Eighty-two per cent had ischaemic strokes. At baseline the median Glasgow Coma Scale score was 15 (interquartile range 15-15) and the mean and median NIHSS scores were 7 and 5 (range 0-34), respectively. The mean oxygen saturation at randomisation was 96.6% in the continuous and nocturnal oxygen groups and 96.7% in the control group. Primary outcome: oxygen supplementation did not reduce disability in either the continuous or the nocturnal oxygen groups. The unadjusted odds ratio for a better outcome (lower mRS) was 0.97 [95% confidence interval (CI) 0.89 to 1.05; = 0.5] for the combined oxygen groups (both continuous and nocturnal together) ( = 5152) versus the control ( = 2567) and 1.03 (95% CI 0.93 to 1.13; = 0.6) for continuous versus nocturnal oxygen. Secondary outcomes: oxygen supplementation significantly increased oxygen saturation, but did not affect any of the other secondary outcomes.
Severely hypoxic patients were not included.
Routine low-dose oxygen supplementation in stroke patients who are not severely hypoxic is safe, but does not improve outcome after stroke.
To investigate the causes of hypoxia and develop methods of prevention.
Current Controlled Trials ISRCTN52416964 and European Union Drug Regulating Authorities Clinical Trials (EudraCT) number 2006-003479-11.
This project was funded by the National Institute for Health Research (NIHR) Research for Patient Benefit and Health Technology Assessment programmes and will be published in full in ; Vol. 22, No. 14. See the NIHR Journals Library website for further project information.
中风是全球范围内主要的死亡和残疾原因。中风后常发生缺氧,且与预后较差有关。氧补充可预防缺氧和继发脑损伤。
(1)评估急性中风患者常规低剂量氧补充是否比不吸氧改善预后;(2)评估夜间仅给予氧(当氧饱和度最有可能低时)是否比连续补充更有效。
多中心、前瞻性、随机、开放、盲终点试验。
设有急性中风病房的二级保健医院。
中风后 24 小时内和中风发作后 48 小时内的成年中风患者,无明确的氧适应证或禁忌证,或无危及生命的其他疾病,除中风外。
通过基于网络的最小化随机分配,分为:(1)连续氧:随机分配后 72 小时内,以 3L/min 的流速(如果基线氧饱和度≤93%)或 2L/min 的流速(如果>93%)通过鼻插管持续给予氧;(2)夜间氧:连续三晚在夜间(21:00-07:00)通过鼻插管给予氧。流速与连续氧组相同;(3)对照组:除非因中风以外的原因需要,否则不常规给予氧补充。
主要结局:通过邮寄问卷在 3 个月时(参与者知情,评估者盲法)评估改良 Rankin 量表(mRS)的残疾程度。次要结局在 7 天:神经改善、国立卫生研究院中风量表(NIHSS)、死亡率以及前 72 小时内的最高和最低氧饱和度。次要结局在 3、6 和 12 个月:死亡率、独立性、当前生活安排、巴氏指数、生活质量(欧洲生活质量-5 维度,三个水平)和诺丁汉扩展日常生活活动量表通过邮寄问卷。
在英国的 136 家医院中,共有 8003 名患者于 2008 年 4 月 24 日至 2013 年 6 月 17 日入组[连续组,n=2668;夜间组,n=2667;对照组,n=2668;平均年龄 72 岁(标准差 13 岁);4398 名(55%)男性]。所有预后因素和基线特征在各组之间均匹配良好。82%的患者患有缺血性中风。基线时格拉斯哥昏迷量表评分为 15 分(四分位间距 15-15),平均和中位数 NIHSS 评分为 7 分和 5 分(范围 0-34)。随机分组时连续和夜间氧组的平均氧饱和度分别为 96.6%和 96.7%,对照组为 96.7%。主要结局:氧补充并不能降低连续或夜间氧组的残疾程度。调整后的更好结局(较低的 mRS)的优势比为 0.97(95%置信区间(CI)为 0.89 至 1.05;=0.5),联合氧组(连续和夜间氧组)(=5152)与对照组(=2567)相比,连续组与夜间组相比,优势比为 1.03(95%CI 为 0.93 至 1.13;=0.6)。次要结局:氧补充显著增加了氧饱和度,但对其他次要结局没有影响。
未纳入严重缺氧患者。
对非严重缺氧的中风患者常规给予低剂量氧补充是安全的,但不能改善中风后的预后。
调查缺氧的原因并开发预防方法。
目前的对照试验(ISRCTN)和欧盟药物监管机构临床试验(EudraCT)编号 2006-003479-11。
本项目由英国国家卫生研究所(NIHR)患者受益和卫生技术评估计划资助,将在;第 22 卷,第 14 期。请访问 NIHR 期刊库网站,了解更多项目信息。